HALO:NASDAQ
Halozyme Therapeutics, Inc.
$108.31
arrow_downward
-1.41%(-1.55) 1D
$108.45
arrow_upward
+0.13% (+0.14)bedtimeAfter hours
Closed: Oct 5, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$109.62
High
$109.87
Low
$107.68
Mkt. cap
12.29B
Avg. vol.
2.21M
Volume
0.00
P/E ratio
32.36
52-wk high
$116.84
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
Open
$109.62
High
$109.87
Low
$107.68
Mkt. cap
12.29B
Avg. vol.
2.21M
Volume
0.00
P/E ratio
32.36
52-wk high
$116.84
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
Simply Wall Street
·
9 minutes ago
Manufacturing Approval Could Change The Case For Alvotech (ALVO) Stock
TradingView
·
1 hour ago
NYSE Owner Starts Gold Futures in London, a Market Without One Since 2022
MarketBeat
·
24 minutes ago
Community West Bancshares (NASDAQ:CWBC) Stock Has Consensus Price Target of $28.17
Seeking Alpha
·
1 hour ago
Cumberland's Monday Memo
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com